Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2009

View Archived Issues

Direct antagonism of NOTCH transcriptional activity shows potent antiproliferative effects in vivo

Interim data from phase I trial of Cortiject in diabetic macular edema disclosed at ISOPT

ABT-263 shows favorable safety and PK profiles in phase I/IIa trial in CLL

Recent data suggest Ontak may enhance endogenous immunity to breast cancer antigens

Treatment with entinostat plus aromatase inhibitor is well tolerated in breast cancer

Novartis discovers novel compounds for the treatment of parasitic infections

Takeda claims glucokinase activators for the treatment of diabetes

Vitae Pharmaceuticals presents 11beta-HSD1 inhibitors for obesity therapy

The University of Utah discloses PKC activators for cancer therapy

Novel muscarinic receptor agonists in early development at Lundbeck

Pfizer's Toviaz superior to Detrol LA in treating urge urinary incontinence

FDA's ODAC recommends not approving Tarceva as first-line NSCLC therapy

InSite Vision to advance new ocular anti-inflammatory candidate ISV-303

FDA's ODAC to review ChemGenex's Omapro for chronic myeloid leukemia

Advanced Life Sciences' Restanza effective against tularemia in nonhuman primates

FDA grants orphan drug designation to Clinuvel's afamelanotide for solar urticaria

Hybrigenics to begin phase IIb efficacy trial of inecalcitol in hormone-refractory prostate cancer

BioAlliance gains French Drug Agency's approval to initiate phase II clonidine trial

Advaxis and GOG begin phase II trial of ADXS11-001 in advanced cervix cancer

ALS TDI and Applied Proteomics complete first stage of collaboration on ALS biomarkers

Syntiron grants Sanofi Pasteur exclusive worldwide license to MRSA vaccine

Nanotherapeutics acquires Oscient's ramoplanin and Epix's PRX-3140

Almac Discovery begins phase I trial of intranasal granisetron spray for CINV

Intercell reports interim data from ongoing phase II trial of P. aeruginosa vaccine

Mayo Clinic licenses molecular breast imaging technology to Gamma Medica-Ideas

Merck & Co. to acquire Avecia's biologics business

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...